MX2019013621A - Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. - Google Patents

Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.

Info

Publication number
MX2019013621A
MX2019013621A MX2019013621A MX2019013621A MX2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A
Authority
MX
Mexico
Prior art keywords
methods
long
receptor agonists
immunotherapeutic compositions
acting interleukin
Prior art date
Application number
MX2019013621A
Other languages
English (en)
Inventor
Zhang Ping
Benedict Kirk Peter
Kuo Brewer Peiwen
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2019013621A publication Critical patent/MX2019013621A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona un agonista del receptor de IL-15 de acción prolongada, composiciones relacionadas y métodos de preparación y uso, por ejemplo, en el tratamiento de afecciones que responden a la terapia efectiva para proporcionar, por ejemplo, actividad inmuno-sostenida y actividad antitumoral.
MX2019013621A 2017-05-15 2018-05-15 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. MX2019013621A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US201862648240P 2018-03-26 2018-03-26
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Publications (1)

Publication Number Publication Date
MX2019013621A true MX2019013621A (es) 2020-01-13

Family

ID=64274790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013621A MX2019013621A (es) 2017-05-15 2018-05-15 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.

Country Status (9)

Country Link
US (1) US12036283B2 (es)
EP (1) EP3624827A4 (es)
JP (2) JP7316222B2 (es)
KR (1) KR20200003922A (es)
CN (1) CN111093688A (es)
AU (2) AU2018270926C1 (es)
CA (1) CA3060410A1 (es)
MX (1) MX2019013621A (es)
WO (1) WO2018213341A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222295A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
MX2021005485A (es) * 2018-11-09 2021-06-18 Nektar Therapeutics Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
CN113677362A (zh) * 2019-04-05 2021-11-19 尼克塔治疗公司 用于增强细胞免疫疗法的方法
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
JP2022533222A (ja) 2019-05-20 2022-07-21 サイチューン ファーマ 癌又は感染性疾患を処置するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト投薬レジメン
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
WO2022090202A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
WO2022268991A1 (en) 2021-06-23 2022-12-29 Cytune Pharma Interleukin 15 variants
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1995013385A2 (en) 1993-11-12 1995-05-18 Gilead Sciences Thrombin mutants
CA2186747C (en) 1994-04-06 2009-01-27 Kenneth H. Grabstein Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
EA013535B1 (ru) 2002-12-26 2010-06-30 Маунтин Вью Фамэсьютикэлс, Инк. Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
MXPA05007348A (es) 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
WO2005030196A2 (en) 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
AR050293A1 (es) 2004-08-11 2006-10-11 Moll Tomas Polipeptidos de interleuquina-15 mutante
US20060104945A1 (en) 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
AU2006259225B2 (en) 2005-06-16 2012-05-31 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
JP5615558B2 (ja) 2007-02-28 2014-10-29 セリナ・セラピユーテイツクス・インコーポレーテツド 活性ポリオキサゾリンおよびそれを含む組成物
SI2237799T1 (sl) 2008-02-01 2019-07-31 Ascendis Pharma A/S Predzdravilo, ki obsega samo-cepljiv linker
CA2737040C (en) 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010048184A2 (en) 2008-10-21 2010-04-29 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
TWI534152B (zh) 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
KR102349549B1 (ko) 2010-11-12 2022-01-11 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
CN102145178B (zh) 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
WO2014201378A1 (en) 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Also Published As

Publication number Publication date
US12036283B2 (en) 2024-07-16
CA3060410A1 (en) 2018-11-22
JP7316222B2 (ja) 2023-07-27
JP2020519676A (ja) 2020-07-02
WO2018213341A1 (en) 2018-11-22
AU2018270926C1 (en) 2022-10-27
AU2018270926A1 (en) 2019-11-07
US20200078467A1 (en) 2020-03-12
KR20200003922A (ko) 2020-01-10
CN111093688A (zh) 2020-05-01
AU2018270926B2 (en) 2022-04-07
EP3624827A4 (en) 2021-03-03
EP3624827A1 (en) 2020-03-25
AU2022203691A1 (en) 2022-06-16
AU2022203691B2 (en) 2023-10-12
JP2023082218A (ja) 2023-06-13

Similar Documents

Publication Publication Date Title
MX2019013621A (es) Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.
MX2021005485A (es) Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2019014960A (es) Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2022012082A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MX2019009660A (es) Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
PH12015502438B1 (en) Compositions and methods for activating ``stimulator of interferon gene``-dependent signalling
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
SG10201809427SA (en) Insulin receptor partial agonists
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
TN2017000375A1 (en) Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2018006996A (es) Composiciones y metodos mejorados para la entrega viral de neoepitopos y usos de estos.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
NZ735736A (en) Acetate salt of buprenorphine and methods for preparing buprenorphine
WO2021081193A8 (en) Methods of administration of il-2 receptor agonists
MX2021005593A (es) Miméticos de interleucina dividida y sus usos.
MX2020004376A (es) Uso de inhibidores de nox para el tratamiento de cancer.